Beijing First Biotech's Human Umbilical Cord Mesenchymal Stem Cell Injection Receives IND Approval for Moderate-to-Severe Allergic Rhinitis

Recently, public information from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) indicated that the “Human Umbilical Cord Mesenchymal Stem Cell Injection” submitted by Beijing First Biotechnology Development Co., Ltd. (Acceptance Number: CXSL2500627) has been approved for clinical trials, with its indication clearly targeting moderate-to-severe allergic rhinitis. This milestone marks a significant breakthrough in the clinical translation of stem cell therapies for allergic diseases.

The core cell culture process for the “Human Umbilical Cord Mesenchymal Stem Cell Injection” utilizes NcMission™ hMSC Medium, a clinical-grade human mesenchymal stem cell medium independently developed by Shouning Biotechnology Co., Ltd. This product is a chemically defined, animal component-free, clinical/pharmaceutical-grade medium suitable for the cultivation of mesenchymal stem cells derived from various tissues, thereby providing critical assurance of quality and safety for cell-based products from the source.